Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764
- April 16, 2018 Apellis Pharmaceuticals Provides Update on Phase 1b Open Label Study of APL-2 in PNH Patients Not Previously Treated with Eculizumab
- March 19, 2018 Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
- February 23, 2018 Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
- February 22, 2018 Apellis Pharmaceuticals Announces 18-Month Results of Phase 2 Study (FILLY) of APL-2 in Geographic Atrophy
- January 2, 2018 Apellis Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
- December 20, 2017 Apellis Finalizes Phase 3 Clinical Trial Plans for Geographic Atrophy Treatment with APL-2
- December 19, 2017 Apellis Pharmaceuticals Expands Management Team, Appoints Timothy Sullivan Chief Financial Officer
- December 8, 2017 Apellis Pharmaceuticals Presents Update on Phase 1b PHAROAH Trial of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) at Annual Scientific Assembly of the International PNH Interest Group (IPIG)
- November 13, 2017 Apellis Pharmaceuticals Announces Closing of its Initial Public Offering
- November 8, 2017 Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
Displaying 261 - 270 of 282